NDC 63759-3032-01 - Bortezomib
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 63759-3032
- Requested NDC
- 63759-3032-01
- Package NDCs from labels
- 63759-3032-1, 63759-3032-01
- Manufacturer
- Shilpa Medicare Limited | Amneal Oncology Private Limited
- Effective date
- 2024-08-30
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Bortezomib - Shilpa Medicare Limited | Amneal Oncology Private Limited | Shilpa Medicare Limited | Amneal Oncology Private Limited | 2024-08-30 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63759-3032-1 | Bortezomib | 1 in 1 CARTON | INJECTION | 1 | 1 | |
| 63759-3032-1 | Bortezomib | 1.4 mL in 1 VIAL, SINGLE-DOSE | INJECTION | 1.4 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 63759-3032 | BORTEZOMIB INJECTION [SHILPA MEDICARE LIMITED] | 1 | Current NDC, 2 package rows | 20240926_61539d49-dc21-4576-8813-4bc8abf3868c.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Bortezomib | BORTEZOMIB | Sintetica US LLC | d79a71ec-b46d-4961-ad05-8980915cba94 | 2023-10-09 | Warnings, Adverse reactions | 69G8BD63PP |
| BORTEZOMIB | BORTEZOMIB | Hospira, Inc. | 9fdf6169-699f-40eb-bda1-760253062b3c | 2023-02-27 | Warnings, Adverse reactions | 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Novadoz Pharmaceuticals LLC | d41340c2-7fe8-42b2-aaa5-c9f9b0e9b50e | 2022-07-20 | Warnings, Adverse reactions | 69G8BD63PP |
| Bortezomib | BORTEZOMIB | BluePoint Laboratories | 12500f21-8e2f-4bcd-861e-4dfca843da2e | 2022-05-16 | Warnings, Adverse reactions | 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Qilu Pharmaceutical Co., Ltd. | aef02171-bf8a-43ad-b40c-7642623f9802 | 2022-05-09 | Warnings, Adverse reactions | 69G8BD63PP |
| BORTEZOMIB | BORTEZOMIB | Zydus Lifesciences Limited | 582c7c0d-fa25-4586-8157-a1e2653d72d9 | 2022-05-05 | 69G8BD63PP | |
| Bortezomib | BORTEZOMIB | Pharmascience Inc. | 191d231a-1fbd-4a65-9d33-d5dc03bac381 | 2022-05-02 | Warnings, Adverse reactions | 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Waverley Pharma Inc | a73d7ea7-d068-4d25-b368-fc3db1898be2 | 2022-04-13 | Warnings, Adverse reactions | 69G8BD63PP |
| bortezomib | BORTEZOMIB | Hikma Pharmaceuticals USA Inc. | 854be921-5fd9-482a-8432-a0c0241625f8 | 2021-11-22 | Warnings, Adverse reactions | 69G8BD63PP |
| Bortezomib | BORTEZOMIB | MAIA Pharmaceuticals, Inc. | c40e6a28-d577-43d4-bca6-bef28da1d580 | 2021-09-22 | Warnings, Adverse reactions | 2608948 69G8BD63PP |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.